Preparation of adrenochrome hydrogel patch, gel, ointment, and the comparison of their blood coagulating and wound healing capability

Materials and Manufacturing Processes

Volumn 21, Issue 3, 2006, Pages 297-301

  Mukherjee, D ^a   Banthia, A K ^a  

^a INDIAN INSTITUTE OF TECHNOLOGY   (India)

Author keywords

Adrenochrome monosemicarbazone; Blood coagulation; Capillary fragility; Controlled release; Cytotoxicity; Drug delivery; Gel; Hemostatic effect; Hydrogel patch; Hydrophilic polymers; Ointment; Synergistic effect; Thromboplastin; Transdermal; Wound healing

Indexed keywords

BIOMEDICAL ENGINEERING; BLOOD; DRUG DOSAGE; GELS; GLYCEROL; PATIENT TREATMENT; POLYVINYL ALCOHOLS; TOXICITY;

ADRENOCHROME MONOSEMICARBAZONE; BLOOD COAGULATION; CAPILLARY FRAGILITY; CONTROLLED RELEASE; CYTOTOXICITY; HEMOSTATIC EFFECTS; HYDROPHILIC POLYMERS; OINTMENTS; THROMBOPLASTIN; WOUND HEALING;

HYDROGELS;

EID: 33645788385     PISSN: 10426914     EISSN: 15322475     Source Type: Journal    
DOI: 10.1080/10426910500464743     Document Type: Article

References (14)

1. Kjalke, M.; Ezban, M.; Monroe, D.M.; Hoffman, M.; Roberts, H.R.; Headner, U. High dose factor VIIa increases initial thrombin generation and mediates faster platelet activation in thrombocytopenia like conditions in cell based models. Br. J. Haematol. 2001, 114, 114-120.
2. Rajeki, M.; Pajunen, P.; Josilahti, P.; Rasi, V.; Vatera, E.; Salomaa, V. Hemostatic factors as predictors of stroke and cardiovascular diseases: the FINRISK '92 hemostasis study. J. Blood Coagulation and Fibrinolysis 2005, 16 (2), 119-124.
3. Meddahi, S.; Bara, L.; Fessi, H.; Samama, M.M. Determination of prothombinase activation after adding human purified prothrombin to human clot: comparison of hirudin, an activated factor II inhibitor, with DX9065a, an activated factor X inhibitor, on clot-associated thrombin and on prothrombin activation. J. Blood Coagulation and Fribinolysis 2005, 16 (2), 125-133.
4. Rapaport, S.I.; Rao, L.M.V. The tissue factor pathway: how it has become a "prima bellerina". Throm. Haemost. 1995, 2, 7-17.
5. Bouma, B.N.; Mosnier, L.O. Thrombin activatable fibrinolysis inhibitor (TAFI) at the interface between coagulation and fibrinolysis. Pathophysiol. Haemos. Thromb. 2004, 33, 375-381.
6. Gialani, D.; Bronze, G.J. Factor XI activation in a revised model of blood coagulation. Science 1991, 2555 (022), 909-912.
7. Naito, K.; Fujiwaka, K. Activation of human blood coagulation factor XI independent of factor XII, factor XIa is activated by thrombin and in presence of negatively charged surfaces. J. Biol. Chem. 1991, 266 (12), 7353-7358.
8. Brown, G.L.; Naney, L.B.; Griffen, J.; Grammer, A.B.; Yancey, J.M.; Curtsinger, L.J. Enhancement of wound healing by topical treatment by epidermal growth factor. J. Medicine 1989, 321, 71-83.
9. MacPherson, J.; Ledger, P.; Ksander, G. The influence of heparin on wound healing in response to collagen implant invivo. Cell Relat. Res. 1998, 8, 83-100.
10. Li, J.K.; Wang, N.; Wu, X.S. Gelatin hydrogel nanoparticles as a protein drug carrier. Proceedings of Int. Biol. Symp, New Orleans, Louisiana, U.S.A, 1997.
11. Yin, Y.; Yang, Y.J; Xu, H. Hydrophobically modified hydrogels containing azoaromatic cross links: Swelling properties, degradation in vivo and application in drug delivery. European Polymer J. 2002, 38, 2305-2311.
12. Swafford, W.B. Carbopol 934 as ephidrene sulphate jelly base. Am. J. Pharm. 1960, 132, 382-384.
13. Fares, H.M.; Zatz, J.L. Measurement of drug release from topical gels using two types of apparatus. Pharm. Tech. 1995, 19 (1), 52-58.
14. Shah, V.P.; Siewert, M.; Dressman, J.; Moeller, H.; Brown, C.K. Dissolution/in vitro drug release testing of special dosage form. www.dissolutiontech.com (accessed February 2002).